GLSI Key Statistics, Chart & Performance
The current stock price of GLSI is 21.9001 USD. In the past month the price increased by 147.73%. In the past year, price increased by 79.87%.
GLSI Latest News, Press Relases and Analysis
GLSI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.35 | 406.76B | ||
| AMGN | AMGEN INC | 15.2 | 179.02B | ||
| GILD | GILEAD SCIENCES INC | 15.24 | 154.86B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.67 | 117.47B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.34 | 82.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 786.55 | 52.99B | ||
| INSM | INSMED INC | N/A | 37.83B | ||
| NTRA | NATERA INC | N/A | 32.17B | ||
| BIIB | BIOGEN INC | 10.57 | 25.96B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.29 | 21.92B | ||
| INCY | INCYTE CORP | 15.31 | 19.30B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About GLSI
Company Profile
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company is headquartered in Stafford Texas, Texas and currently employs 4 full-time employees. The company went IPO on 2020-09-25. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. The company has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer.
Company Info
GREENWICH LIFESCIENCES INC
3992 Bluebonnet Dr, Building 14
Stafford Texas TEXAS 33954 US
CEO: Snehal Patel
Employees: 4
Phone: 12034343290
GREENWICH LIFESCIENCES INC / GLSI FAQ
What does GLSI do?
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company is headquartered in Stafford Texas, Texas and currently employs 4 full-time employees. The company went IPO on 2020-09-25. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. The company has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer.
What is the current price of GLSI stock?
The current stock price of GLSI is 21.9001 USD. The price increased by 5.87% in the last trading session.
Does GLSI stock pay dividends?
GLSI does not pay a dividend.
What is the ChartMill rating of GREENWICH LIFESCIENCES INC stock?
GLSI has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is GREENWICH LIFESCIENCES INC worth?
GREENWICH LIFESCIENCES INC (GLSI) has a market capitalization of 303.32M USD. This makes GLSI a Small Cap stock.
Can you provide the short interest for GLSI stock?
The outstanding short interest for GREENWICH LIFESCIENCES INC (GLSI) is 24.47% of its float.
GLSI Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to GLSI. When comparing the yearly performance of all stocks, GLSI is one of the better performing stocks in the market, outperforming 96.65% of all stocks.
GLSI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GLSI. No worries on liquidiy or solvency for GLSI as it has an excellent financial health rating, but there are worries on the profitability.
GLSI Financial Highlights
Over the last trailing twelve months GLSI reported a non-GAAP Earnings per Share(EPS) of -1.46. The EPS decreased by -82.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -511.58% | ||
| ROE | -891.34% | ||
| Debt/Equity | 0 |
GLSI Forecast & Estimates
8 analysts have analysed GLSI and the average price target is 42.84 USD. This implies a price increase of 95.62% is expected in the next year compared to the current price of 21.9001.